Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Core Viewpoint - Acasti Pharma Inc. is rebranding to Grace Therapeutics, reflecting its historical roots and scientific innovation, with a focus on advancing its lead drug candidate GTx-104 for treating aneurysmal subarachnoid hemorrhage (aSAH) [1][2] Company Overview - Acasti Pharma Inc. will begin trading under the new name Grace Therapeutics on Nasdaq with the symbol "GRCE" starting October 28, 2024 [1] - The company has made significant progress in the clinical development of GTx-104, including full enrollment of the STRIVE-ON trial, with data expected in early 2025 and a New Drug Application (NDA) submission anticipated in the first half of 2025 [2][3] Product Development - GTx-104 is a novel injectable formulation of nimodipine designed for intravenous infusion in aSAH patients, addressing significant unmet medical needs [4][5] - The U.S. addressable market for GTx-104 is estimated to be approximately $300 million based on market research [5] Corporate Strategy - The company has restructured to an agile biopharma model, rebuilt its management team, prioritized its pipeline, divested legacy assets, and re-domiciled to the U.S. as a Delaware corporation [3] - These strategic steps are expected to enhance the company's attractiveness to potential strategic partners and global institutional investors [3] Upcoming Events - A virtual Key Opinion Leader (KOL) event on GTx-104 is scheduled for November 20, 2024, to discuss its application in aSAH [3]